30-Second Takeaway
- Closed-loop invasive ventilation improves safety metrics but not ventilator-free days versus protocolized conventional modes.
- Low-flow HFNC (20–30 L/min) appears optimal for AECOPD, balancing gas exchange, comfort, and nasal/facial injury risk.
- Full MIST2 intrapleural enzyme dosing is rare but associated with fewer escalations, less bleeding, and shorter hospitalization.
- Transudative effusions from organ failure carry high one-year mortality with identifiable prognostic markers.
- Incident PAH patients frequently receive less than guideline-recommended combination therapy, including many high-risk patients.
Week ending December 13, 2025
Practice-changing signals in ventilation, pleural disease, airway obstruction, and pulmonary vascular care
Closed-loop ventilation improves safety but not ventilator-free days
In this multicenter RCT of 1201 intubated ICU adults, early INTELLiVENT adaptive support ventilation did not increase ventilator-free days versus protocolized conventional ventilation. Median ventilator-free days at day 28 were nearly identical between groups, with no difference in 28-day mortality or ventilation duration among survivors. Closed-loop ventilation improved ventilation quality and reduced severe hypercapnia and hypoxemia episodes. Rescue therapies, mainly prone positioning, were required less often with closed-loop ventilation, but survival remained unchanged.
Low-flow HFNC likely optimal for AECOPD exacerbations
This Bayesian network meta-analysis included 40 RCTs with 3597 AECOPD patients comparing initial HFNC flow settings and NIV. HFNC showed intubation rates similar to NIV, supporting it as an alternative in appropriate patients. Low-flow HFNC (20–30 L/min) significantly reduced PaCO₂, improved pH, and decreased nasal and facial injuries versus higher flows. Moderate-flow HFNC (30–50 L/min) shortened hospital stay but did not match low-flow performance for gas exchange and tolerability. SUCRA rankings favored low-flow HFNC as the preferred initial setting for AECOPD management.
Full MIST2-dose intrapleural therapy remains uncommon but advantageous
This retrospective cohort from 21 hospitals included 1730 adults with complicated parapneumonic effusion or empyema treated with intrapleural enzyme therapy. Only 5.7% of encounters received full MIST2 dosing, defined as six doses of alteplase and dornase with at least two doses daily for two days. Facility-level variation in full-dose use was high despite minimal comorbidity or severity differences between full-dose and reduced-dose recipients. Full MIST2 dosing was associated with lower hazard of treatment escalation or bleeding compared with nonstandard dosing. Full dosing also correlated with about a 15% reduction in hospital length of stay, supporting implementation where feasible.
Subclinical RA-ILD is frequent and associated with distinct risk markers
Prospective studies report subclinical interstitial lung disease in roughly 25% of patients with rheumatoid arthritis. Risk increases with older age, male sex, smoking, higher CRP and ESR at RA diagnosis, and greater RA disease activity scores. RF and anti-CCP positivity, the MUC5B promoter variant, and elevated MMP-7, PARC, and surfactant protein D further enrich risk. ACR and ACCP guidelines now address ILD screening in RA, but the best management of subclinical disease is unknown. Future research should define high-risk groups for screening and whether early treatment modifies progression to clinical ILD.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.